The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU
Launched by ANKARA CITY HOSPITAL BILKENT · Mar 15, 2021
Trial Information
Current as of June 04, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants hospitalized in the intensive care unit diagnosed with COVID-19 will incluse in the study
- Exclusion Criteria:
- • there is no exclusion criteria
About Ankara City Hospital Bilkent
Ankara City Hospital Bilkent is a leading healthcare institution in Turkey, dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals, the hospital fosters a collaborative environment for conducting rigorous scientific investigations. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the highest level of integrity, ultimately contributing to the development of new therapies and enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
betül aytaç, MD
Principal Investigator
ankara ch bilkent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials